Drug intelligence / Profile preview

WAS-2111

Development stage: Unknown
Lead developer: Wassermann Medic
Modality: Small Molecules
Administration: Oral

Overview

WAS-2111 is an investigational oral small molecule being developed by Wassermann Medic in collaboration with Almirall for the treatment of Th2-driven inflammatory diseases, such as atopic dermatitis. It functions as a histamine H4 receptor (H4R) antagonist. The H4 receptor is primarily expressed on hematopoietic cells, including mast cells, eosinophils, and T cells, and plays a key role in mediating chemotaxis and cytokine production in inflammatory responses. By blocking H4R, WAS-2111 aims to inhibit the inflammatory cascade associated with Th2-mediated conditions. As of 2024, the compound is in Phase 1 clinical development to evaluate its safety, tolerability, and pharmacokinetics.

Other names: SMOL-Wasserman Medic-small molecule-oral-Th2-driven diseases

Targets

HRH4 (Histamine H4 receptor)

Beyond the preview

Go deeper on WAS-2111.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on WAS-2111.

Explore the full profile